Chemours Co Stock Performance
CC Stock | USD 25.91 0.57 2.15% |
The firm shows a Beta (market volatility) of 1.48, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Chemours will likely underperform. Chemours right now shows a risk of 5.68%. Please confirm Chemours jensen alpha, maximum drawdown, and the relationship between the coefficient of variation and sortino ratio , to decide if Chemours will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Chemours Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound fundamental indicators, Chemours is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return 0.42 | Five Day Return (2.11) | Year To Date Return (16.68) | Ten Year Return 27 | All Time Return 27 |
Forward Dividend Yield 0.0379 | Payout Ratio 0.3311 | Forward Dividend Rate 1 | Dividend Date 2024-03-15 | Ex Dividend Date 2024-02-23 |
Chemours dividend paid on 15th of March 2024 | 03/15/2024 |
1 | Levi Korsinsky Notifies The Chemours Company Investors of a Class Action Lawsuit and Upcoming Deadline CC | 04/04/2024 |
2 | The Chemours Company Sued for Securities Law Violations - Contact Levi Korsinsky Before May 20, 2024 to Discuss Your Rights CC | 04/08/2024 |
3 | The Chemours Company Class Action Levi Korsinsky Reminds The Chemours Company Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of Ma... | 04/10/2024 |
4 | May 20, 2024 Deadline Contact Levi Korsinsky to Join Class Action Suit Against - CC | 04/11/2024 |
5 | Levi Korsinsky Notifies Shareholders of The Chemours Company of a Class Action Lawsuit and an Upcoming Deadline | 04/12/2024 |
6 | CLASS ACTION NOTICE Kessler Topaz Meltzer Check, LLP Reminds The Chemours Company Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors... | 04/15/2024 |
7 | Class Action Filed Against The Chemours Company - May 20, 2024 Deadline to Join - Contact Levi Korsinsky | 04/16/2024 |
8 | Levi Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2024 in The Chemours Company Lawsuit - CC | 04/18/2024 |
Begin Period Cash Flow | 1.1 B |
Chemours |
Chemours Relative Risk vs. Return Landscape
If you would invest 2,951 in Chemours Co on January 20, 2024 and sell it today you would lose (303.00) from holding Chemours Co or give up 10.27% of portfolio value over 90 days. Chemours Co is generating 0.0051% of daily returns and assumes 5.6823% volatility on return distribution over the 90 days horizon. Put differently, 50% of stocks are less risky than Chemours on the basis of their historical return distribution, and some 99% of all equities are expected to be superior in generating returns on investments over the next 90 days. Expected Return |
Risk |
Chemours Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Chemours' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Chemours Co, and traders can use it to determine the average amount a Chemours' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 9.0E-4
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | CC |
Estimated Market Risk
5.68 actual daily | 50 50% of assets are less volatile |
Expected Return
0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Chemours is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Chemours by adding Chemours to a well-diversified portfolio.
Chemours Fundamentals Growth
Chemours Stock prices reflect investors' perceptions of the future prospects and financial health of Chemours, and Chemours fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Chemours Stock performance.
Return On Equity | -0.26 | ||||
Return On Asset | 0.0529 | ||||
Profit Margin | (0.04) % | ||||
Operating Margin | 0.07 % | ||||
Current Valuation | 7.02 B | ||||
Shares Outstanding | 148.88 M | ||||
Price To Earning | 25.49 X | ||||
Price To Book | 5.35 X | ||||
Price To Sales | 0.65 X | ||||
Revenue | 6.03 B | ||||
Gross Profit | 1.62 B | ||||
EBITDA | 220 M | ||||
Net Income | (238 M) | ||||
Cash And Equivalents | 1.1 B | ||||
Cash Per Share | 7.73 X | ||||
Total Debt | 4.3 B | ||||
Debt To Equity | 2.94 % | ||||
Current Ratio | 1.82 X | ||||
Book Value Per Share | 4.96 X | ||||
Cash Flow From Operations | 556 M | ||||
Earnings Per Share | (1.60) X | ||||
Market Capitalization | 3.94 B | ||||
Total Asset | 8.25 B | ||||
Retained Earnings | 1.78 B | ||||
Working Capital | 1.35 B | ||||
Current Asset | 2.3 B | ||||
Current Liabilities | 1.47 B | ||||
About Chemours Performance
To evaluate Chemours Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Chemours generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Chemours Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Chemours market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Chemours's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 104.64 | 65.68 | |
Return On Tangible Assets | (0.03) | (0.03) | |
Return On Capital Employed | (0.02) | (0.01) | |
Return On Assets | (0.03) | (0.03) | |
Return On Equity | (0.32) | (0.31) |
Things to note about Chemours performance evaluation
Checking the ongoing alerts about Chemours for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Chemours help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Chemours had very high historical volatility over the last 90 days | |
The company generated the yearly revenue of 6.03 B. Annual Net Loss to common stockholders was (238 M) with gross profit of 1.62 B. | |
Chemours has a strong financial position based on the latest SEC filings | |
Over 77.0% of the company shares are held by institutions such as insurance companies | |
On 15th of March 2024 Chemours paid $ 0.25 per share dividend to its current shareholders | |
Latest headline from accesswire.com: Levi Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2024 in The Chemours Company Lawsuit - CC |
- Analyzing Chemours' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Chemours' stock is overvalued or undervalued compared to its peers.
- Examining Chemours' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Chemours' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Chemours' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Chemours' stock. These opinions can provide insight into Chemours' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chemours Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Chemours information on this page should be used as a complementary analysis to other Chemours' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Chemours Stock analysis
When running Chemours' price analysis, check to measure Chemours' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemours is operating at the current time. Most of Chemours' value examination focuses on studying past and present price action to predict the probability of Chemours' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chemours' price. Additionally, you may evaluate how the addition of Chemours to your portfolios can decrease your overall portfolio volatility.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Chemours' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemours. If investors know Chemours will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemours listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.91) | Dividend Share 1 | Earnings Share (1.60) | Revenue Per Share 40.473 | Quarterly Revenue Growth 0.017 |
The market value of Chemours is measured differently than its book value, which is the value of Chemours that is recorded on the company's balance sheet. Investors also form their own opinion of Chemours' value that differs from its market value or its book value, called intrinsic value, which is Chemours' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemours' market value can be influenced by many factors that don't directly affect Chemours' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemours' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemours is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemours' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.